Literature DB >> 3274208

Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies.

M Delezé1, C V Oria, D Alarcón-Segovia.   

Abstract

Ten of 12 patients with systemic lupus erythematosus (SLE) who had hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) during their course had evidence of antiphospholipid antibodies either because they had a false positive VDRL test (8 patients), a prolonged partial thromboplastin time (5 patients), a lupus anticoagulant (3/4 patients), and/or anticardiolipin antibodies as determined by an ELISA method (7 patients). Antibodies to cardiolipin were found in very high levels (up to 38 standard deviations above the mean of normal controls) and were of both IgG and IgM isotypes. The 2 patients with SLE and Evans' syndrome who did not have evidence of antiphospholipid antibodies were studied at the onset of SLE which occurred with Evans' syndrome. Although cardiolipin is not a constituent of the cell wall of either platelets or erythrocytes, other phospholipids that cross react antigenically with cardiolipin are and can be exposed through cell damage. This could be a mechanism whereby hemolytic anemia and thrombocytopenia could occur in the same patient with SLE. Whether absorption of the antiphospholipid antibody during the acute episode of hemocytopenia could occur, and thus prevent its detection at such time, remains undetermined.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3274208

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

1.  Antiphospholipid antibodies: which and when?

Authors:  R Cervera; J Font; M A Khamashta; G R Hughes
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

2.  Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients.

Authors:  R Cervera; J Font; A López-Soto; F Casals; L Pallarés; A Bové; M Ingelmo; A Urbano-Márquez
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

3.  Disseminated zygomycosis and systemic lupus erythematosus.

Authors:  C A Bloxham; S Carr; D W Ryan; P J Kesteven; R S Bexton; I D Griffiths; J Richards
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

4.  Antiphospholipid antibodies, lupus-like disease and the "primary" antiphospholipid syndrome.

Authors:  R A Asherson; M A Khanashta; G R Hughes
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

Review 5.  Antiphospholipid antibodies. A marker for thrombosis and recurrent abortion.

Authors:  M A Khamashta; G R Hughes
Journal:  Clin Rev Allergy       Date:  1994

6.  Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations.

Authors:  J Font; R Cervera; A Lopez-Soto; L Pallares; X Bosch; S Ampurdanes; F J Casals; M Ingelmo
Journal:  Clin Rheumatol       Date:  1989-12       Impact factor: 2.980

Review 7.  Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment.

Authors:  S Giannouli; M Voulgarelis; P D Ziakas; A G Tzioufas
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

8.  Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study.

Authors:  G D Sebastiani; G Passiu; M Galeazzi; F Porzio; U Carcassi
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

9.  Pregnancy outcome in women with antiphospholipid antibodies.

Authors:  A K al-Momen; S A Moghraby; M O el-Rab; A M Gader; S R al-Balla; A A al-Meshari; L al-Nuaim
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

10.  Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders.

Authors:  S Loizou; C Cofiner; A P Weetman; M J Walport
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.